NICE guidance calls for quicker diagnosis of PMOS
Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.
Ipsen's M&A team strikes again, adding Memo in $700m deal
Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.
FDA clears Orca's cell therapy Tregzi for GvHD
Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.
Anthropic launches Claude Science for pharma researchers
Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.
Despite study bust, Vistagen still hopes to file anxiety dru...
Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The globe’s longest-standing, industry-dedicated forum for precision medicine is back.
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc